Endoscopic treatment for greater trochanteric pain syndrome: one-year outcomes and comorbidity impact

Abstract

To evaluate the clinical outcomes of endoscopic treatment for greater trochanteric pain syndrome (GTPS) and to assess the influence of comorbidities such as anxiety-depressive syndrome (ADS) and fibromyalgia on recovery.

Between January and April 2023, 26 endoscopic procedures for GTPS were retrospectively analyzed. Patients included were ≥18 years, presented with GTPS lasting more than six months, and had failed conservative management including physiotherapy, infiltrations, and shockwave therapy. All underwent endoscopic bursectomy and cruciform iliotibial band release. Outcomes were assessed at baseline, 3, 6, and 12 months using the Visual Analogue Scale (VAS), modified Harris Hip Score (mHHS), and Hip Outcome Score for Activities of Daily Living (HOS-ADL) and Sports Subscale (HOS-SS).

Of the 25 patients (26 hips) included, 80.8% were women, with a mean age of 53.4 years. Statistically significant improvements (p < 0.05) were observed in all functional scores at 3 and 6 months. Improvements in VAS, mHHS, and HOS-ADL persisted at 12 months, while HOS-SS plateaued. ADS was present in 46.2% of patients. Although these patients had lower baseline scores, postoperative outcomes were not significantly different compared to non-ADS patients.

Endoscopic treatment of GTPS provides early and sustained functional improvement. The presence of anxiety- depressive syndrome or fibromyalgia does not appear to adversely impact surgical outcomes.